Get notified when CRIS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (worsened) — Going concern disclosure now references $5.1M cash at year-end (down from $20.0M prior year) and explicitly states insufficient cash for 12 months even after January 2026 financing.
Curis sells Erivedge royalties, raises $18.6M, narrows focus to two trials amid 29% headcount cut
Filed March 24, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~1 min read
Key Changes
-
high
Sold Erivedge royalty stream for $2.5M plus release of $34M liability, eliminating only revenue source but generating one-time $27M accounting gain. Company now entirely pre-revenue.
MD&A: Erivedge Sale verify on EDGAR → -
high
Raised $18.6M in January 2026 PIPE but disclosed insufficient cash for 12 months even after financing. Cash fell from $20M to $5.1M year-over-year; going concern warning worsened.
Notes: Going Concern verify on EDGAR → -
high
Strategic pivot announced alongside 29% workforce reduction (34 to 24 employees), terminated AML programs, and sale of only revenue asset, suggesting aspirational rather than executed positioning.
Business: Strategic Refocus verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade CRIS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify